![Harbor BioSciences, inc.](/news-release/logo/218777/0/218777.jpg?lastModified=12%2F09%2F2016%2023%3A56%3A56&size=2)
Harbor BioSciences Apoptone(R) for Prostate Cancer Shows Activity at All Doses Tested
June 07, 2010 14:19 ET
|
Harbor BioSciences, Inc.
CHICAGO, June 7, 2010 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (Nasdaq:HRBR) today presented new positive data from its ongoing Phase I/IIa clinical trial with Apoptone® (HE3235) for...
![Harbor BioSciences, inc.](/news-release/logo/218777/0/218777.jpg?lastModified=12%2F09%2F2016%2023%3A56%3A56&size=2)
Harbor BioSciences Announces $2.06 Million Equity Financing
June 07, 2010 08:44 ET
|
Harbor BioSciences, Inc.
SAN DIEGO, June 7, 2010 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (Nasdaq:HRBR) announced today that it has entered into an agreement with certain institutional investors to raise approximately...
![Harbor BioSciences, inc.](/news-release/logo/218777/0/218777.jpg?lastModified=12%2F09%2F2016%2023%3A56%3A56&size=2)
Harbor BioSciences Apoptone(R) Clinical Results Poster Selected for ASCO Annual Meeting
May 17, 2010 08:00 ET
|
Harbor BioSciences, Inc.
SAN DIEGO, May 17, 2010 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (Nasdaq:HRBR) today announced that new data from the Phase I/IIa clinical trial of the company's lead drug candidate...
![Harbor BioSciences, inc.](/news-release/logo/218777/0/218777.jpg?lastModified=12%2F09%2F2016%2023%3A56%3A56&size=2)
Triolex(R) Demonstrates Evidence of Anti-Inflammatory Activity in a Phase IIa Clinical Trial in a Subset of Type 2 Diabetes Mellitus Patients
May 10, 2010 08:00 ET
|
Harbor BioSciences, Inc.
SAN DIEGO, May 10, 2010 (GLOBE NEWSWIRE) -- Harbor Biosciences (Nasdaq:HRBR), a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory...
![Harbor BioSciences, inc.](/news-release/logo/218777/0/218777.jpg?lastModified=12%2F09%2F2016%2023%3A56%3A56&size=2)
Harbor BioSciences Announces Listing Transfer to The Nasdaq Capital Market
March 17, 2010 16:30 ET
|
Harbor BioSciences, Inc.
SAN DIEGO, March 17, 2010 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (Nasdaq:HRBR) today announced that NASDAQ has approved its application to transfer its stock listing to The Nasdaq Capital Market...
![Harbor BioSciences, inc.](/news-release/logo/218777/0/218777.jpg?lastModified=12%2F09%2F2016%2023%3A56%3A56&size=2)
Harbor BioSciences Reports New Phase I/IIa Data at ASCO Symposium and Announces Plans to Advance Prostate Cancer Treatment Apoptone(R) to Phase IIb
March 08, 2010 08:00 ET
|
Harbor BioSciences, Inc.
SAN DIEGO, March 8, 2010 (GLOBE NEWSWIRE) -- Harbor BioSciences Inc. (Nasdaq:HRBR) said today it had reported encouraging data from its ongoing Phase I/IIa clinical trial with Apoptone® (HE3235)...
![Harbor BioSciences, inc.](/news-release/logo/218777/0/218777.jpg?lastModified=12%2F09%2F2016%2023%3A56%3A56&size=2)
Harbor BioSciences to Present Results on Lead Drug Candidate Apoptone(R)
March 01, 2010 08:30 ET
|
Harbor BioSciences, Inc.
SAN DIEGO, March 1, 2010 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (Nasdaq:HRBR) today announced it will present a poster at the ASCO Genitourinary Cancers Symposium in San Francisco this week,...